<?xml version="1.0" encoding="UTF-8"?>
<p id="Par115">Cost-utility, cost-effectiveness, and budget impact analyses performed on QALYs (Quality-Adjusted Life Years) and ICERs (Incremental Cost-Effectiveness Ratios) calculation based on EQ-5D-3L questionnaire will provide useful and complementary information in order (i) to recommend the best strategy to adopt; (ii) to estimate the budget impact on the French National Health Insurance of the generalization of the cost-effective strategy [
 <xref ref-type="bibr" rid="CR27">27</xref>–
 <xref ref-type="bibr" rid="CR29">29</xref>]. Analyses will be performed comparing SBRT versus conventional treatment without SBRT in solid tumors patients with ≤3 bone-only metastasis. Incremental costs between both arms will be compared to incremental health improvement.
</p>
